Scarica l'app Stockscreener
0.9898
0.31%
0.0031
Pre-mercato:
.99
0.0002
+0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9867
Aprire:
$0.99
Volume 24 ore:
563.59K
Relative Volume:
0.63
Capitalizzazione di mercato:
$102.52M
Reddito:
-
Utile/perdita netta:
$-93.61M
Rapporto P/E:
-0.4691
EPS:
-2.11
Flusso di cassa netto:
$-71.16M
1 W Prestazione:
-7.50%
1M Prestazione:
+9.95%
6M Prestazione:
-15.40%
1 anno Prestazione:
-21.13%
Intervallo 1D:
$0.9602
$1.02
Intervallo di 1 settimana:
$0.95
$1.09
Portata 52W:
$0.8319
$2.11
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Confronta IMUX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
0.9898 | 102.52M | 0 | -93.61M | -71.16M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
Immunic (IMUX) Projected to Post Earnings on Wednesday - Defense World
Immunic CMO on Celiac Disease Awareness Month, potential of IMU-856 - Proactive financial news
Reviewing Psyence Biomedical (NASDAQ:PBM) and Immunic (NASDAQ:IMUX) - Defense World
Immunic eyes Phase 3 after MS disability gains in Phase 2 CALLIPER trial - Proactive financial news
36,811 Shares in Immunic, Inc. (NASDAQ:IMUX) Acquired by Invesco Ltd. - Defense World
Immunic (IMUX) Stock Price, News & Analysis - MarketBeat
Where Do Analysts See Immunic Inc (NASDAQ: IMUX) Heading? - Stocksregister
Renaissance Technologies LLC Grows Position in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Immunic’s (IMUX) Buy Rating Reiterated at D. Boral Capital - Defense World
Immunic (NASDAQ:IMUX) Earns Buy Rating from HC Wainwright - Defense World
Immunic to Participate in Scientific and Industry Conferences in May | IMUX Stock News - GuruFocus
Immunic to Participate in Scientific and Industry Conferences in May - The Malaysian Reserve
Immunic presses ahead with MS drug despite Phase II endpoint miss - Yahoo
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Pr - GuruFocus
What is Immunic Inc (IMUX) Stock Return on Shareholders’ Capital? - Sete News
Daily Progress: Immunic Inc (IMUX) Drop -22.65, Closing at 0.99 - DWinneX
MS drug shows promise in progressive cases, despite missed trial goal - The Pharma Letter
Immunic (IMUX) Price Target Raised to $22 by Brookline Following Positive Trial Data | IMUX Stock News - GuruFocus
Immunic Inc (IMUX) rating initates by William Blair - knoxdaily.com
How will Immunic Inc’s (IMUX) earnings compare to estimates this quarter? - uspostnews.com
Small cap wrap: ReconAfrica, Power Metallic, Immunic, Replenish Nutrients... - Proactive Investors
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
Immunic Announces Vidofludimus Calcium Reduced Risk of Disabilit - GuruFocus
Immunic reports reduced disability worsening in progressive multiple sclerosis trial - Proactive financial news
Immunic (IMUX) Reports Promising Phase 2 Results for Vidofludimu - GuruFocus
Immunic (IMUX) Shares Fall on Phase 2 Trial Results for Multiple Sclerosis Drug - GuruFocus
IMUX: HC Wainwright & Co. Reiterates "Buy" Rating with $10.00 Price Target | IMUX Stock News - GuruFocus
Immunic Announces Vidofludimus Calcium Reduced Risk Of Disability Worsening By 30% In Primary Progressive Multiple Sclerosis Patients From Phase 2 Calliper Trial - marketscreener.com
Immunic reports progress in multiple sclerosis trial - Investing.com Australia
Immunic stock drops after mid-stage trial data (IMUX:NASDAQ) - Seeking Alpha
Immunic Inc Inc. (IMUX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial | IMUX Stock News - GuruFocus
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial - Yahoo Finance
Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher (NASDAQ:IMUX) - Seeking Alpha
Immunic Inc (IMUX) Offers An Excellent Investment Opportunity At Current Levels - Stocksregister
One Immunic Insider Raised Their Stake In The Previous Year - Yahoo Finance
Trading Day Review: Immunic Inc (IMUX) Gains Momentum, Closing at 1.14 - DWinneX
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $13.20 - Defense World
IMUX: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Immunic Inc (IMUX) stock on the rise: An overview - uspostnews.com
Immunic’s (IMUX) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Has Optimistic View of Immunic FY2025 Earnings - Defense World
HC Wainwright Estimates Immunic’s Q1 Earnings (NASDAQ:IMUX) - Defense World
Immunic, Inc. (NASDAQ:IMUX) Is Expected To Breakeven In The Near Future - simplywall.st
Immunic Stock Price, Quotes and Forecasts | NASDAQ:IMUX - Benzinga
Immunic, Inc. Announces Closing of $5.1 Million Registered Direc - GuruFocus
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode - MSN
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - The Malaysian Reserve
Immunic Closes of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - citybiz
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments - Eastern Progress
Immunic Raises $5.1 Million From Direct Stock Offering - marketscreener.com
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):